Needham reiterated a Hold rating for ResMed (NYSE:RMD), highlighting the company's second quarter fiscal year 2025 performance. ResMed reported revenue and earnings per share (EPS) that surpassed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback